Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / HSP90a



This biomarker is also known as:
  • HSPCAL4,
  • FLJ31884,
  • heat shock 90kD protein 1, alpha-like 4,
  • HSP89A,
  • HSP90A,
  • heat shock 90kDa protein 1, alpha,
  • heat shock protein 90kDa alpha (cytosolic), class A member 1,
  • Hsp89,
  • HSP 86,
  • heat shock 90kD protein, alpha-like 4,
  • Renal carcinoma antigen NY-REN-38,
  • HSPCAL1,
  • HSPC1,
  • HSP90AA1,
  • LAP2,
  • HSP90N,
  • HSP86,
  • renal carcinoma antigen NY-REN-38,
  • heat shock 86 kDa,
  • HSPCA,
  • Heat shock 86 kDa,
  • Hsp90,
  • heat shock protein HSP 90-alpha,
  • heat shock 90kD protein 1, alpha,
  • HSPN,

View in BioMuta


The HSP90AA1 protein, also known as HSP90a, is a molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved in cell cycle control and signal transduction. HSP90AA1 is a homodimer that assists in the proper folding of specific target proteins by use of an ATPase activity that is modulated by co-chaperones. Two transcript variants encoding different isoforms have been found for this gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


HSP90a is important for the stability of and function of a wide range of oncoproteins and has been been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker.

Performance Comment

It has been shown that levels of HSP90a were elevated in lung cancer patients, and that the levels of HSP90a increased along with the clinical state of the NSCLC. HSP90a has been shown to participate in the metastasis of lung cancer. HSP90A is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.